Document:

Exhibit 10.22

 

CONFIDENTIAL TREATMENT REQUESTED:

 

Portions of this Exhibit have
been redacted pursuant to a request for confidential treatment under Rule 24b-2
of the General Rules and Regulations under the Securities Exchange Act of
1934, as amended.  Such redacted portions have been replaced with “{***}” in this Exhibit.  An unredacted version of this document has
been filed separately with the Securities and Exchange Commission along with
the request for confidential treatment.

 

29th October, 2002

 

Stephen
Jones

Lifehealth Limited

23 Winkfield Road

Windsor

Berkshire

SL4 4BA

 

Dear
Stephen,

 

ISOMERIC
DEVELOPMENTS OF TETRABENAZINE

 

I
thought it would be useful for both of us to have recorded in writing our
agreement reached on 4 July concerning the participation of Lifehealth in
the proposed isomeric developments of tetrabenazine. As you know, there were
two proposed isomeric developments that we discussed. The first was the
development of the isomers of the trans form of
tetrabenazine and the second involved the development of the isomers of
dihydrotetrabenazine derived from the cis form of
tetrabenazine.

 

The
isomers of the trans form of tetrabenazine

 

It
was agreed that Lifehealth and Cambridge would {***}† the costs of this
development. We will obviously keep you fully apprised of all aspects of this
development as we progress and we welcome your input and approval on the
direction and costs of that development. This development will constitute an “Improvement”
pursuant to our existing licence agreement and as a result, the intellectual
property rights will be jointly owned by Lifehealth and Cambridge and all other
restrictions regarding licensing of those rights set forth in the various
clauses of our agreement will apply.

 

Development
of the isomers of dihydrotetrabenazine resulting from the cis
form of tetrabenazine

 

When
we discussed this at the meeting on 4 July, you expressed the view that
Lifehealth did not want to be involved, at this stage, in this development and
did not want to share with Cambridge 

 

† Represents
material which has been redacted and filed separately with the Securities and
Exchange Commission pursuant to a request for confidential treatment pursuant
to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

 

 

any
costs of the development. You also said that you and Lifehealth had no
objections to Cambridge pursuing that development at its own cost. We have
decided that we will continue with that development. Cambridge will bear all
costs of this development and we have already put in place accounting measures
to separate the costs of this project from those associated with the “trans”
project. We would also like to confirm that, as this development will fall
outside the licence agreement, Cambridge will own all intellectual property
rights arising from this development.

 

 

I
would be grateful if you could confirm your agreement to the above by return
letter.

 

Very
best wishes,

 

Yours
sincerely,

 

	
  /s/
  MARK EVANS

  	
   

  
	
   

  	
   

  
	
  MARK
  EVANS

  	
   

  

 

 

	
   

  	
  I hereby confirm my agreement to the above

  
	
   

  	
   

  
	
   

  	
  /s/ STEPHEN JONES

  	
  1/11/02

  
	
   

  	
   

  
	
   

  	
  FOR
  LIFEHEALTH LTDExhibit 10.23

 

CONFIDENTIAL TREATMENT REQUESTED:

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934, as amended.  Such
redacted portions have been replaced with “{***}” in this
Exhibit.  An unredacted version of this document has
been filed separately with the Securities and Exchange Commission along with
the request for confidential treatment.

 

31st March, 2004

 

Stephen Jones,

Forest Edge,

23 Winkfield Road,

Windsor,

Berks.

SL4 4BA

 

Dear Stephen,

 

Cambridge has, with the approval of Lifehealth,
entered into a revised agreement with Celltech Pharma S.A. regarding the right
to distribute tetrabenazine in Spain and Portugal (hereinafter “the Spanish
Agreement”). The Spanish Agreement provides for both the payment to Cambridge
by Celltech of an upfront sum in consideration for development costs and the
possibility of Cambridge having to refund all or part of that payment in certain
circumstances.

 

Provision is made in the 1998 agreement between
Lifehealth and Cambridge for the sharing of any up front payment but no
provision exists to cover the situation whereby any up front payment has to be
refunded in whole or in part. Lifehealth and Cambridge hereby agree that the
upfront payment received from Celletech shall be shared in accordance with
clause 6.8. Lifehealth and Cambridge also agree to {***}† any reimbursement of
the whole or any part of the payment received from Celltech. In the event that
such a reimbursement is rightly due pursuant to the provisions of the Spanish
Agreement Cambridge shall inform Lifehealth of such and Lifehealth shall pay to
Cambridge an amount equal to {***}† of the sum to be refunded to Celltech. Cambridge
shall thereafter make payment to Celltech of the whole of the sum to be
refunded.

 

Please indicate your agreement to such by signing in
the space provided and returning to us this letter.

 

	
  Very
  best wishes,

  	
   

  
	
   

  	
   

  
	
  /s/
  MARK EVANS

  	
   

  
	
   

  	
   

  
	
  MARK EVANS

  	
   

  

 

 

† Represents material which has been redacted and
filed separately with the Securities and Exchange Commission pursuant to a
request for confidential treatment pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934, as amended.

 

 

	
  For
  and on behalf of

  	
   

  
	
  CAMBRIDGE
  LABORATORIES LIMITED

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  /s/
  STEPHEN JONES

  	
   

  
	
   

  	
   

  
	
  STEPHEN
  JONES

  	
   

  
	
   

  	
   

  
	
  For
  and on behalf of

  	
   

  
	
  LIFEHEALTH LIMITEDExhibit 10.24

 

CONFIDENTIAL TREATMENT REQUESTED:

 

Portions of this Exhibit have been redacted pursuant to a request
for confidential treatment under Rule 24b-2 of the General Rules and
Regulations under the Securities Exchange Act of 1934, as amended.  Such
redacted portions have been replaced with “{***}” in this
Exhibit.  An unredacted version of this document has
been filed separately with the Securities and Exchange Commission along with
the request for confidential treatment.

 

12th August, 2004

 

Stephen Jones

Lifehealth Limited

23 Winkfield Road

Windsor

Berkshire

SL4 4BA

 

Dear Stephen

 

Cambridge Ireland

 

Thank you for your letter of
9th August. We appreciate your concerns. We will ensure, and shall put systems
in place to ensure, that where the new group structure of Cambridge results in
duplication of costs or incremental costs, the additional costs, over and above
what would have been taken into account in the calculation of the {***}† had
Cambridge not changed its structure, shall not be taken into account in that
calculation of the {***}† under the contract.

 

On the question of the
currency, the exchange rate issue from the US sales will be no different to
what it is now. Cambridge Ireland (CLI) will be paid in $US the same way
Cambridge Laboratories (CLUK) is now. Clause 6.7 regarding times and rates of
conversions to Sterling will continue to apply.

 

With regard to legal costs
Allistair is keeping all costs relating to the restructuring entirely separate
from general tetrabenazine related costs so there is no possibility of overlap.
There won’t be many other instances where legal costs would be incurred in
relation to a tetrabenazine related matters that wouldn’t have been incurred in
the normal way.

 

As the details of this
arrangement are now set out in four different letters I think you will agree it
is in both our interests to record everything in one document that we can both
sign.

 

† Represents material which
has been redacted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended.

 

 

Overall Structure

 

We are moving certain
operations to Ireland to avail ourselves of some of the tax advantages
available in Ireland. With regard to tetrabenazine this means procurement,
sales and dossier development work will be moved to CLI.

 

All the distribution
agreements for tetrabenazine currently in the name of CLUK will be assigned to
CLI and CLI will assume all those obligations. All future distribution
agreements for tetrabenazine will be entered into by CLI. CLI will take over
the obligations of CLUK under the agreements for the manufacture of
tetrabenazine. CLI will also enter into an agreement for distribution of certain
products in the UK, including tetrabenazine, with CLUK. CLI will enter into a
services agreement with CLUK pursuant to which CLUK will provide certain
services to CLI including pharmacovigilance, medical information and scientific
services.

 

Agreements
for Assignment

 

With regard to
tetrabenazine, you have agreed to the assignment of the following agreements
from CLUK to CLI:

 

1.                                       The original license agreements between
CLUK and Lifehealth of 1995 and 1998 and all amendments, alterations and side
letters.

2.                                       The Synkem, Pharmaserve and Boots
manufacturing agreements and all amendments, side letters, alterations and
technical agreements. Please note that the new manufacturing agreement to
replace the one with Boots will be in the name of CLI.

3.                                       All tetrabenazine distribution agreements
and letters of appointment currently in force and all amendments, alterations
and side letters. This means our agreements and arrangements with AOP, AFT,
Orphan Australia, Medifront, Medilink, Megapharm, OPI, Celltech Spain, Prestwick
(both the US agreement and the Canadian), Paesel Lorei, Fagron and Chiesi.
Please note that future distribution agreements will be in the name of CLI.

 

Calculation of {***}†

 

With the exception of sales
in the UK, all revenue will be earned by CLI in the same way it is now earned
by CLUK.

 

CLI will obviously also be
incurring a number of the costs that are deductible in the calculation of the
{***}† However, CLUK will also be incurring some of those costs. As agreed we
will ensure, and shall put systems in place to ensure, that where the new group
structure of Cambridge results in duplication of costs or incremental costs,
the additional costs, over and above what would have been taken into account in
the calculation of the {***}† had Cambridge not changed its structure, shall
not be taken into account in that calculation of the {***}† under the contract.

 

† Represents material which
has been redacted and filed separately with the Securities and Exchange
Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended.

 

2

 

Running
through the deductibles set out in the definition:

 

{***}†

 

Sales in the UK

 

CLUK will continue to be
responsible for UK sales and sales of the existing UK stock whether in the UK
or elsewhere.

 

In respect of the UK sales
and any other sales of the existing UK stock the figure used for calculations
will be the revenue earned by CLUK, not CLI. We will of course not be double
accounting in respect of the UK sales so you will not be {***}† of both CLI and
CLUK arising from UK sales and other sales of the existing UK stock.

 

The costs of the existing UK
stock will be a CLUK cost that will be accounted for in the usual way. Once
that stock has run out CLI will be incurring the cost of goods and that cost
will be accounted for in the usual way.

 

You will obviously see and
have the right to comment on the distribution agreement that will be put in
place between CLI and CLUK.

 

Accounting to you

 

We will provide you with a
group reconciliation statement concerning {***}† that reflects the above. That
statement will set out how much you have to invoice to both CLI and CLUK. You
will receive payments from both CLUK and CLI.

 

Consent

 

Could you please, on behalf
of Lifehealth Limited, indicate Lifehealth’s consent to these assignments
taking place, the sub-distribution agreement between CLI and CLUK and the
amendment to the agreement reflecting the new accounting arrangements by
signing this letter in the space provided and returning it to me.

 

† Represents material which has been redacted
and filed separately with the Securities and Exchange Commission pursuant to a
request for confidential treatment pursuant to Rule 24b-2 under the Securities
Exchange Act of 1934, as amended.

 

3

 

Many thanks and very best
wishes.

 

Yours sincerely

 

	
  /s/ MARK EVANS

  	
   

  

 

	
  Mark Evans

  	
   

  
	
  Chief Executive Officer

  	
   

  

 

 

Signed by

 

	
  /s/ STEPHEN JONES

  	
   

  

 

	
  Stephen Jones

  	
   

  
	
  Director

  	
   

  
	
  Lifehealth Limited

  	
   

  

 

Dated:   15 / 8 / 04

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]